Welcome
Support Centre
21 November 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Does vitamin D improve markers of vascular health in stroke patients?
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN28737567
Date ISRCTN assigned01/05/2007
Local reference number(s)Res/A107
Public titleDoes vitamin D improve markers of vascular health in stroke patients?
Scientific title
AcronymN/A
Disease/condition/study domainStroke
Study hypothesisThat a single dose of oral vitamin D can lower blood pressure and improve endothelial function in stroke patients
Design/methodologyDouble blind, randomised, placebo controlled trial.
Research ethics reviewPending as of 21 February 2007.
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Clinical diagnosis of completed stroke (ischaemic or haemorrhagic)
2. Serum 25-hydroxy vitamin D level <50 nmol/L
Participants - exclusion criteria1. Hyper- or hypocalcaemia
2. Metastatic malignancy
3. Liver function tests over three times limit of normal
4. Estimated Glomerular Filtration Rate (GFR) <40 ml/min
5. Previous clinical diagnosis of osteomalacia
6. Taking vitamin D preparations
7. Unable to give written informed consent
8. Unable to swallow tablets orally
9. Atrial fibrilation (to provide a more homogeneous aetiology)
Patient information material
Anticipated start date01/06/2007
Anticipated end date30/11/2008
Status of trialOngoing
Target number of participants68 (two groups of 34)
InterventionsA single oral dose of 100,000 U ergocalciferol (vitamin D) or placebo.
Primary outcome measure(s)Blood pressure (seated office and 24 hour measurements) will be measured at baseline and then at 8 and 16 weeks after vitamin D administration.
Secondary outcome measure(s)The secondary outcomes will also be measured at baseline and then at 8 and 16 weeks after vitamin D administration.

1. Endothelial function
2. B-type natriuretic peptide
3. Heart rate variability
Sources of fundingChest Heart and Stroke Scotland (UK)
Sponsor nameUniversity of Dundee (UK)
Sponsor detailsResearch and Innovation Services
Dundee
United Kingdom
DD1 4HN
Sponsor telephone+44 (0)1382 384664
Sponsor fax+44 (0)1382 386765
Sponsor emailj.z.houston@dundee.ac.uk
Contact nameDr Miles Witham
Contact detailsDepartment of Medicine & Therapeutics
University of Dundee
Ninewells Hospital & Medical School
Dundee
United Kingdom
DD1 9SY
Contact telephone+44 (0)1382 632436
Contact fax+44 (0)1382 660675
Contact emailm.witham@dundee.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN28737567
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central